CEO: Genine Winslow, MSc

Visit Website

Chameleon Bioscience’s EVADER technology is a transformative platform that “cloaks” Adeno Associated Virus (AAV) based vectors to make them invisible to immune activation. The result is AAV based drugs with greater safety, greater potency, reduced CMC risk and potential for repeat dosing as shown in preclinical models. EVADER technology can be used to expand addressable markets for existing AAV gene therapies, for producing novel gene therapies, and has potential to address rare diseases as well as much larger disease markets. 

Chameleon is developing a pipeline of 3 products for genetic diseases that have rapid paths to clinical data and commercialization: Niemann-Pick Type C (NPC), and Severe Hemophilia A & B. Niemann-Pick Type C (NPC) is a rare disease affecting 1 in 120,000 live births; the average life expectancy of those suffering from the disease is two years.